Research and develop innovative pharmaceutical products for various therapeutic areas. Now — the numbers.
This is an established company with proven profits.
Average growth of 20% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $977.8M would still be left in the vault — a solid cushion for hard times.
The market pays 18.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 60% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 20% a year on average.
There is $2.9B in the vault; even if every debt were paid off, $977.8M would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Against everything we grade, DSKYF lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: DSKYF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.